Evidence map›Paper›PMID 16059829›Full record

ReviewSeminars in reproductive medicine2005

Oocyte maturation: the coming of age of a germ cell.

Michelle Jamnongjit, Stephen R Hammes

Abstract readReview
In one paragraph

Review in Seminars in reproductive medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 121 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The role of omentin-1 in female reproduction: a critical review.The Journal of reproduction and development · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. The spectrum ofFrontiers in endocrinology · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Oocyte Competence Biomarkers Associated With Oocyte Maturation: A Review.Frontiers in cell and developmental biology · 2021
    Review
  19. Fertility Options for the Transgender and Gender Nonbinary Patient.The Journal of clinical endocrinology and metabolism · 2020
    Review
  20. Transgender Men and the Gynecologist.Clinical obstetrics and gynecology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michelle JamnongjitDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA.
Stephen R Hammes
The University of Texas Southwestern Medical Center · US

Funding

MECHANISMS OF DRUG ACTION AND DISPOSITIONT32GM007062 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI MANGELSDORF, DAVID J · 1985 to 2020
$7.4M
Nongenomic Steroid Signaling in OocytesR01DK059913 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HAMMES, STEPHEN R. · 2002 to 2009
$2.8M
NIDDK NIH HHS DK59913NIDDK NIH HHS R01 DK059913NIGMS NIH HHS T32 GM007062NIGMS NIH HHS T32 GM07062-29
6 · The paper itself

Abstract

Normal female fertility relies on proper development of the oocyte. This growth culminates just prior to ovulation, when oocyte maturation occurs. Oocyte maturation refers to a release of meiotic arrest that allows oocytes to advance from prophase I to metaphase II of meiosis. This precisely regulated meiotic progression is essential for normal ovulation and subsequent fertilization, and involves changes in the delicate balance between factors promoting meiotic arrest and others that are stimulating maturation. Most of the inhibitory mechanisms appear to involve the upregulation of intracellular cyclic adenosine monophosphate levels. These processes may include direct transport of the nucleotide into oocytes via gap junctions, G protein-mediated stimulation of adenylyl cyclase, and inhibition of intracellular phosphodiesterases. In contrast, potential factors that play roles in triggering oocyte maturation include gonadotropins (e.g., follicle-stimulating factor and luteinizing hormone), growth factors (e.g., amphiregulin and epiregulin), sterols (e.g., follicular fluid-derived meiosis-activating sterol), and steroids (e.g., testosterone progesterone, and estradiol). Delineating the complex interactions between these positive and negative components is critical for determining the role that oocyte maturation plays in regulating follicle development and ovulation, and may lead to novel methods that can be used to modulate these processes in women with both normal and aberrant fertility.

Indexed as

AnimalsFemaleFertilityGerm CellsGrowth SubstancesHormonesHumansMeiosisOocytesOogenesisOvarian DiseasesOvaryGrowth SubstancesHormones

Identifiers

PMID16059829
PMCPMC1482430
OpenAlexW2075552931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.